Niagen Bioscience — Third Quarter 2026 Earnings Summary

Niagen Bioscience, Inc. reported third-quarter 2026 net sales of $27.2 million, a decrease from the prior year, driven by $23.3 million in Tru Niagen revenue. The company posted a net loss of $1.2 million but achieved positive adjusted EBITDA of $0.5 million and generated $2.6 million in operating cash flow for the quarter. Strategic initiatives during the period included the launch of Niagen Plus At-Home Injections, the introduction of the Niagen NanoCloud skincare line, and a new brand campaign featuring Kelly Slater. Additionally, the company expanded its retail footprint to nearly 300 GNC and Sam's Club locations and announced a clinical trial partnership with Mass General Brigham.